NCT05626712招募中1 期
Clinical Trial to Evaluate the Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 Diabetes (CREATE-1)
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 18
- 试验地点
- 2
- 主要终点
- Number of Participants with Adverse Events
研究概览
简要总结
The brief purpose of this research study is to learn about the safety and efficacy of intra-arterial administration of CELZ-201 in patients with newly diagnosed Type 1 Diabetes Mellitus (T1D).
详细描述
The proposed study is a Phase I/IIa randomized, controlled clinical trial to evaluate CELZ-201 therapy as an intervention for the treatment of recent onset Type 1 Diabetes. The objective is to determine the safety and efficacy of CELZ-201 administration, based on the timing and dose of CELZ-201 treatment. Subjects who meet eligibility criteria will be randomized to treatment or control groups, in a 2:1 ratio. Subjects in the Group I (Treatment Group, n=12) will receive standard of care for type 1 diabetes and CELZ-201 within 1 month from enrollment (within 1 year of diagnosis). Subjects in Group II (Control Arm, n=6) and will receive enhanced standard of care for type 1 diabetes.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 35 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject must be able to understand and provide signed informed consent.
- •Males and females, 18-35 years of age.
- •Diagnosis of T1D within 1 year, with stimulated C-peptide peak level >0.6 ng/mL as assessed by 4-hour MMTT at the time of Visit 0 (screening).
- •Diagnosed with T1D, according to ADA standard criteria, and confirmed by positivity to at least two islet autoantibodies, GAD65, IA-2, or ZnT
- •Mentally stable and able to comply with the procedures of the study protocol
- •Subjects must be willing to comply with "standard-of-care" diabetes management.
- •Subjects with eGFR >80 ml/min/1.73m2
- •Female subjects of childbearing potential must have a negative pregnancy test upon study entry.
- •Female (and male) subjects with reproductive potential must agree to use two FDA approved methods of birth control for the entire duration of the study.
- •Potential subjects of childbearing potential should agree to use effective contraception for the entire 2-year period.
- •Adequate venous access to support study required blood draws.
排除标准
- •Inability or unwillingness of a subject to give written informed consent or comply with study protocol.
- •BMI>28 kg/m.
- •HbA1c > 9%
- •Subjects with poorly controlled hypertension as defined by systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg.
- •Subjects with any history of cardiac disease, including but not limited to myocardial infarction, uncompensated heart failure, fluid overload, as well as any clinically significant abnormality identified on prior cardiac stress test, angiogram evaluation, or echocardiogram.
- •Subjects with liver disease, portal hypertension, any coagulopathy (including history of Factor V deficiency) or long-term anti-coagulant therapy (except low-dose aspirin). Other hepatic conditions including hepatic anatomic abnormalities or variants that would place the individual at increased risk in the judgment of the investigator are also considered exclusionary.
- •Symptomatic cholecystolithiasis; acute or chronic pancreatitis; or current symptomatic peptic ulcer disease.
- •Subjects with uncontrolled thyroid disease: thyroid stimulating hormone <0.3 mU/L or >5 mU/L; free T4 <5.0 ug/dL or >11.0 ug/dL.
- •Any of the following laboratory findings: hemoglobin <11.5 g/dL (females) or <13.2 g/dL (males); leukocytes <3,000/μL; neutrophils <1,500/μL; lymphocytes <800/μL; platelets <100,000/μL; elevation in AST and ALT >2 x ULN (upper limit of normal); LDL cholesterol >160; Triglycerides >3 x ULN; total bilirubin >1.5 x ULN.
- •Screening laboratory evidence consistent with significant chronic active infection (i.e.., hepatitis B and C, tuberculosis, and HIV), and IGRA Tuberculosis (Tb) test during screening
- •Ongoing acute infections, e.g., acute respiratory tract, urinary tract, or gastrointestinal tract infections.
- •Subjects with eating disorders.
- •Ongoing or anticipated use of diabetes medications other than insulin.
- •Current or ongoing use of non-insulin pharmaceuticals that affect glycemic control within 7 days of screening.
- •Recent recipient of any licensed or investigational live attenuated vaccine(s) within 6 weeks of randomization.
- •Patients who have participated in previous clinical studies, other than observational studies, will be excluded.
- •Concomitant therapy with immunosuppressive drugs, immunomodulators, or cytotoxic agents, or previous therapy less than 3 months from randomization.
- •History or diagnosis of malignancy with the exception of a history of localized basal or squamous cell carcinoma.
- •Any history of gastroparesis or other severe gastrointestinal disease.
- •Presence of an allograft.
- •Diagnosed or self-reported drug or alcohol abuse.
- •An individual who has a medical, psychological or social condition that, in the opinion of the Principal Investigator, would interfere with safe and proper completion of the trial.
- •Pregnancy or ongoing breastfeeding for women; unwillingness or inability of both females and males of childbearing age to use a reliable and effective form of contraception, for the entire 2-year duration of the study.
- •Inability to perform any of the assessments required for endpoint analysis.
- •Known history of serious allergic reactions, including anaphylaxis to CELZ-201 or its preparation components. Specifically, patients with a prior history of heparin induced thrombocytopenia or any other adverse reaction to heparin, will be excluded.
- •The investigator believes that participating in the trial is not in the best interest of the patient, or the investigator considers patient unsuitable for enrollment (such as unpredictable risks or subject compliance issues).
- •Positive for coronavirus disease (COVID)-19 by PCR or evidence of active infection per local institutional standards.
- •Allergy to iodine contrast or anesthesia
- •For female subjects: Pregnant, nursing, or planning to become pregnant during the course of entire duration of the study (approximately little over two years) or unwillingness to comply with contraceptive requirements.
- •For male subjects: Male subjects with a female partner who is planning to become pregnant with the male subject during the entire course of the study or unwillingness to comply with contraceptive requirements.
研究组 & 干预措施
CELZ-201 Treatment Group
Experimental
Participants in this group will receive a single dose of CELZ-201, in addition to standard of care of care for Type 1 Diabetes treatment.
干预措施: CELZ-201 Administration (Biological)
Control Group
Placebo Comparator
Participants in this group will receive standard of care for Type 1 Diabetes only.
干预措施: Control Group (Other)
结局指标
主要结局
Number of Participants with Adverse Events
时间窗: 6 months
The primary outcome to be assessed is tolerability and safety of the CELZ-201 therapy. The incidence of adverse events (grade 2 or above as per CTCAE version 5.0) in both groups at 6 months.
次要结局
- Alloreactive Antibody Levels(12 months)
- Number of Participants with Adverse Events(24 months)
- Islet Autoantibody Levels(12 months)
- Glycosylated HbA1C(12 months)
- Insulin Requirement(12 months)
- C-peptide during a 4-hour MMTT(12 months)
- Number of Participants with Adverse Events(12 months)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
Safety and Clinical Effectiveness of Intravitreal Bevacizumab (Lumiere®) in Patients With Wet Age-related Macular Degeneration (Wet AMD)Age-Related Macular DegenerationNCT03668054Laboratorio Elea Phoenix S.A.22
尚未招募
不适用
Reperfusion With Hypothermia in Acute Ischemic StrokeIschemic StrokeRevascularizationEndovascular TreatmentReperfusion InjuryNCT05676957Liping Liu30
已完成
3 期
Safety and Efficacy of the CryoCor™ Cardiac Cryoablation System for the Treatment of Atrial FlutterAtrial FlutterNCT00113178Boston Scientific Corporation160
撤回
2 期
Cri Analog PG1 Effectiveness and Safety in Covid-19Covid19NCT04536363Alonso Vera Torres
Unknown
1 期
Evaluation of Safety and Exploratory Efficacy of an Autologous Adipose-derived Cell Therapy Product for Treatment of Single Knee OsteoarthritisKnee OsteoarthritisNCT04043819Personalized Stem Cells, Inc.125